Er riktig som det sies at det ikke brukes mindre cellegift med bruk av Amphinex, men det brukes vel strengt tatt til å innkapsle cellegiften og målrettet åpnes der svulstene er. Selv om det er lik dose med cellegift, så vil cellegiften kun utløses i kroppen fritt der lyset brukes for å åpne opp. Slik jeg har forstått så er det slik at de stedene hvor en ikke bruker lys så vil cellene selv konsumere cellegiften (i løpet av ca 2 uker) uten at den lekkes ut i kroppen dersom lys ikke tilføyes. Det vil isåfall slik jeg forstår det potensielt redusere bivirkningene av behandlingen.
7 Likes
This is not a new presentation but I have a question on slide 6
It’s says Pci enhances significantly the effect of 3 widely used cancer drugs, we know that this is the case with gemcitabine and bleomycin, what the 3rd one ? Do they mean ciplastin here?
https://docplayer.net/storage/27/9847020/1534513746/CnCud6kOE8GfBhJwh9Uk8g/9847020.pdf
4 Likes
I remember hearing Per Walday say in context of amphinex treatment that they knew that their technology enhances gemcitabin. However, he did at that time not mentioned cisplatin, so the third one I suppose is still a mystery! Maybe someone else knows?
4 Likes
The present report aims to investigate if PCI may exert direct cytotoxic effects on endothelial cells. PCI of saporin was performed on endothelial human umbilical vein endothelial cell (HUVEC) and fibrosarcoma cells (HT1080) using two PCI-relevant photosensitizers, TPPS2a and AlPcS2a. A 22- and 13-fold higher photosensitizer uptake was detected in the endothelial cells compared with the HT1080 cells for AlPcS2a and TPPS2a, respectively. PCI of saporin was, however, found more effective in HT1080 cells. For HT1080 cells, PCI with saporin increased cell killing 1.9-fold over photodynamic therapy alone, but under the same conditions, only increased HUVEC cell killing by 1.6- and 1.3-fold with AlPcS2a and TPPS2a , respectively. Saporin uptake was higher in HUVECs than in the HT1080 cells, hence did not reflect the cell line differences in PCI efficacy. This is the first report on PCI-mediated kill of endothelial cells and lays the foundation for further preclinical evaluation of the PCI technology as an antivascular strategy to ablate tumors.
4 Likes
Slik jeg tolker det må vi dele i to steg.
Steg 1) Dag 0 får man Amphinex og dag 4 får man en enkel dose med Gemcitabine (1000 mg/m2) + lys noen timer senere.
Steg 2) 7 til 21 dager senere starter man på 8 sykluser med cellegift. Her snakker vi Gemcitabine (1000 mg/m2) og Cisplatin (25 mg/m2) som blir gitt dag 1 og 8 i hver syklus som er på 21 dager.
(I extension-studiet fikk man også en ekstra behandling tilsvarende del 1 i slutten av syklus 4 med cellegift).
Ser vi på steg 1 så får man altså Amphinex og dag 4 får man Gemcitabine som fraktes med blodet og blir tatt opp i kreftcellene. Cellegiften blir her fanget/innkapslet i endosomet og når derfor ikke målet. Det er altså derfor man noen timer senere lyser på kreftcellene. Dette aktiverer Amphinex slik at membranet i endosomet ødelegges og Gemcitabine kan angripe målet.
Ser vi på steg 2 så blir dette gitt etter belysning og mesteparten av cellegiften (Gem-Cis) vil fortsatt skade både syke og friske celler som før (endog med forhåpentligvis større effekt på syke celler). I extension-studiet vil man forhåpentligvis se at andre PCI-behandling gir enda bedre effekt enn første - men det får vi nok vite om få uker.
Når du sier at cellene selv konsumerer cellegiften så påvirker dette også friske celler, selv om disse ofte vil kunne reparere skader på DNA. Med andre ord tolker jeg det som at cellegiften fortsatt gir de samme bivirkningene - bare at man her får bivirkninger som lyssensitivtet i tillegg pga Amphinex.
Korriger meg gjerne dersom det jeg sier er feil eller du (eller andre) har link til informasjon som tilsier at man i dette studiet får mindre bivirkninger i forhold til behandling uten Amphinex.
@Boykie eller @Snoeffelen har kanskje noen tanker rundt bivirkninger i dette studiet kontra dagens anbefalte behandling?
6 Likes
@laplagam thanks for the reply, seems I found the three widely cancer drugs Pci is referring to from an older presentation see below
8 Likes
this is a 2017 publication for pci in sarcoma indication, Kristian Berg is a co-writer.
Conclusion:
The results indicate PCIBLM as a potential novel treatment strategy for soft tissue sarcomas, with antioxidant enzymes, in particular GPx1, and the P53 status as potential predictive markers for response to PCIBLM.
https://www.ncbi.nlm.nih.gov/m/pubmed/28838761/
About Sarcoma:
https://www.cancer.org/cancer/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html
5 Likes
Mye god graving, StockDZ. Takk for at du deler.
Hadde man fått uttelling for prekliniske forsøk så skulle vi vært rike som PCIB-aksjonærer. Uansett godt lesestoff frem til Q2 hvor vi forhåpentligvis får servert gode nyheter fra extension-studiet.
3 Likes
PCI and Prostate cancer
I found this full PhD thesis from UCL (university college London) from 2016 titled: Light-based therapies in Prostate Cancer treatment
It has both in vitro and in vivo studies for prostate cancer (using PCI and PDT) and also a whole chapter (chapter-5) on Stimulation of the immune system following PDT and PCI in Prostate Cancer.
http://discovery.ucl.ac.uk/1532467/1/Martinez%20de%20Pinillos%20Bayona_A_e-THESIS%2018.12.16.pdf
5 Likes
Ikke lenge til neste runde med innsidekjøp kommer:
I fjor solgte ledelsen mange av aksjene fra de innløste opsjonene for å dekke kjøpspris og skatt. Blir spennende å se om de har enda større tro på eget selskap i år og bruker litt egne penger også 
5 Likes
August 17, 2018
“FDA Grants Accelerated Approval to Nivolumab for Small Cell Lung Cancer”.
De fikk AA basert på Fase 1/2 resultater…
“2 (11%) patients had a partial response and 1 (0.9%) patient had a complete response.”…
4 Likes
I guess this is a good news for FimaNac:
FDA Approves Patisiran, First-Ever RNAi Therapeutic Approved for Clinical Use
5 Likes
This is related to the extension study as per REK website, there are two links the second link comes with some updates to the treatment protocol:
Quote:
“4) Det vil bli tatt et større volum med blod (et tillegg på 162 ml over ca. 6 mnd) i den utvidede fase I delen for å se på mulige immune effekter av PCI behandlingen og farmakokinetikken ved andre gangs PCI, samt at det tas blodprøve for analyse av platinum før og etter andre gangs PCI behandling.”
This probably means we will also get more information on the immune response in addition to safety and efficacy 
6 Likes
PCI Biotech initiates research collaboration with Bavarian Nordic
Exploring synergies between proprietary technologies to further enhance the effect of novel therapeutic applications in cancer and infectious diseases
Oslo (Norway) 20 August 2018 . PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that it is initiating a preclinical research collaboration with Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) Kvistgaard, Denmark, a clinical stage biopharmaceutical corporation focused on developing state-of-the-art cancer immunotherapies and vaccines for infectious diseases.
In brief, the collaborators will evaluate technology compatibility and synergy based on in vivo studies. The companies will evaluate results achieved from this research collaboration and then explore the potential for a further partnership.
Per Walday, CEO of PCI Biotech, said: .I.m very pleased to announce another research agreement with a key player within the field of immunotherapies, which is the second collaboration initiated this year. We believe that the PCI technology has the potential to play a role in the realisation of several new therapeutic modalities, and we look forward to explore synergies with Bavarian Nordic.s unique and innovative technologies…
Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fima_Chem_ (enhancement of chemotherapeutics for localised treatment of cancer), fima_Vacc_ (T-cell induction technology for therapeutic vaccination), and fima_NAc_ (nucleic acid therapeutics delivery).Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company.s lead fima_Chem_ programme consists of a clinical Phase I/II study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fima_Vacc_ applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fima_NAc_ utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Nyheten er levert av GlobeNewswire.
http://www.netfonds.no/quotes/release.php?id=20180820.GlobeNewswire.GNW1000095996-en
16 Likes
gjelder dette FimaVacc eller FimaNAc ?
Dybdeanalysen av FimaVacc ble jo startet i mai18 og ble guidet å ta ca 3mnd. så de har nok mye data på denne allerede…
2 Likes
Er utrolig spent på svaret fra TekBot nå. Hvor mye arbeid har PDX lagt inn i botten tro… 
9 Likes
Spennende å se eierskapet i Bavarian Nordic, Johnsen & Johnsen eier over 5% av selskapet!
4 Likes
5,77 %
3 Likes